Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY

Annals of Clinical and Translational Neurology Pub Date : 2025-07-15 DOI:10.1002/acn3.70142

Nabil K. El Ayoubi, Fares Fahd, Hani Tamim, Salem Hannoun, Mark Bal, Elham El-Hallak, Samia J. Khoury

{"title":"Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis","authors":"Nabil K. El Ayoubi, Fares Fahd, Hani Tamim, Salem Hannoun, Mark Bal, Elham El-Hallak, Samia J. Khoury","doi":"10.1002/acn3.70142","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti-CD20 therapy on clinical and sub-clinical outcomes in multiple sclerosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Clinical information was collected prospectively on Research Electronic Data Capture. Patients with age ≥ 18 years old, confirmed diagnosis of multiple sclerosis, treatment with B-cell depleting drug (Rituximab and Ocrelizumab), and minimum follow-up of 12 months with at least 3 clinical visits and at least 3 infusions of medication were included and divided into an extended interval dosing group, a standard interval dosing group, and a converters group who switched from standard to extended interval dosing. Retinal measures were obtained using spectral domain Optical Coherence Tomography. Magnetic resonance imaging acquisitions were performed in two centers using a standardized conventional imaging protocol for multiple sclerosis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Patients had a median clinical follow-up of 3.5 (0.44–7.3) years, retinal OCT follow-up of 2.6 (1.4) years, and MRI follow-up of 2.6 (1.1) years. Annualized changes in clinical measures, retinal measures, and brain volumetric measures were similar between the 3 groups. Multivariate regression analyses also showed no differences.</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>We found no differences in clinical or sub-clinical outcomes between patients treated with standard interval dosing, patients converting from standard to extended interval dosing, and patients on extended interval dosing of B-cell depleting drugs.</p>\n </section>\n </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":"12 10","pages":"2086-2096"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.70142","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.70142","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti-CD20 therapy on clinical and sub-clinical outcomes in multiple sclerosis.

Methods

Clinical information was collected prospectively on Research Electronic Data Capture. Patients with age ≥ 18 years old, confirmed diagnosis of multiple sclerosis, treatment with B-cell depleting drug (Rituximab and Ocrelizumab), and minimum follow-up of 12 months with at least 3 clinical visits and at least 3 infusions of medication were included and divided into an extended interval dosing group, a standard interval dosing group, and a converters group who switched from standard to extended interval dosing. Retinal measures were obtained using spectral domain Optical Coherence Tomography. Magnetic resonance imaging acquisitions were performed in two centers using a standardized conventional imaging protocol for multiple sclerosis.

Results

Patients had a median clinical follow-up of 3.5 (0.44–7.3) years, retinal OCT follow-up of 2.6 (1.4) years, and MRI follow-up of 2.6 (1.1) years. Annualized changes in clinical measures, retinal measures, and brain volumetric measures were similar between the 3 groups. Multivariate regression analyses also showed no differences.

Interpretation

We found no differences in clinical or sub-clinical outcomes between patients treated with standard interval dosing, patients converting from standard to extended interval dosing, and patients on extended interval dosing of B-cell depleting drugs.

Abstract Image

查看原文本刊更多论文

利妥昔单抗或奥克雷单抗治疗多发性硬化症标准与延长间隔剂量的比较效果

目的：我们旨在研究标准和个性化延长间隔剂量抗cd20治疗对多发性硬化症临床和亚临床结局的比较效果。方法：前瞻性收集研究电子数据采集的临床资料。纳入年龄≥18岁、确诊为多发性硬化症、接受b细胞消耗药物（利妥昔单抗和奥克雷单抗）治疗、至少随访12个月、至少3次临床就诊和至少3次输注药物的患者，并将其分为延长间隔给药组、标准间隔给药组和从标准间隔给药转换为延长间隔给药的转换组。视网膜测量采用光谱域光学相干断层扫描。磁共振成像采集在两个中心使用标准化的多发性硬化症常规成像方案进行。结果：患者的临床随访中位数为3.5（0.44-7.3）年，视网膜OCT随访为2.6（1.4）年，MRI随访为2.6（1.1）年。临床测量、视网膜测量和脑容量测量的年化变化在三组之间相似。多变量回归分析也显示无差异。解释：我们发现接受标准间隔剂量治疗的患者，从标准间隔剂量转为延长间隔剂量的患者，以及延长间隔剂量的b细胞消耗药物患者的临床或亚临床结局没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)

CiteScore

9.10

自引率

1.90%

发文量

218

审稿时长

8 weeks

期刊介绍： Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.